Novavax, Inc.

NASDAQ:NVAX   3:59:51 PM EDT
46.16
-0.38 (-0.83%)
Other Pre-Announcement

Novavax Reports Qtrly Revenue Of $704 Million And Qtrly EPS Of $2.56

Published: 05/09/2022 22:44 GMT
Novavax, Inc. (NVAX) - :novavax - Qtrly Revenue of $704 Million Versus $447 Million ; Qtrly Earnings per Share $2.56.
Novavax - Continued Development, Assessment of Strain Change, Including Omicron-specific Clinical Studies With Topline Readout Expected in Q3.
Novavax - Reiterating Full Year 2022 Total Revenue Guidance of Between $4 Billion and $5 Billion.
Novavax - Expect to Initiate Prevent-19 Phase 3 Trial in Younger Age Groups (5-11 Yrs) by Q3.
Novavax - Cash, Cash Equivalents and Restricted Cash Were $1.6 Billion As of March 31, 2022 Versus $1.5 Billion As of December 31, 2021.
Further Company Coverage: Nvaxo ((reuters.
Briefs@thomsonreuters.
Com;)).